J&J joins $10.6M round for developer of stem cell treatment

07/11/2013 | Xconomy

Stem cell startup ViaCyte secured $10.6 million in a private equity funding round in which Johnson & Johnson, the Johnson Trust and Sanderling Ventures participated. The funding matches the $10.1 million grant approved last year by the California Institute for Regenerative Medicine to support clinical trials of ViaCyte's encapsulated cell therapy product, VC-01, for treatment of type 1 and insulin-dependent type 2 diabetes.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC